Clinical trial · Observational
Safety and Efficacy of Firmagon® (Degarelix) for Injection
Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Firmagon® (Degarelix) for Injection
NCT02886598CI-TRIAL-00039100completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| degarelix | Drug | Degarelix | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Firmagon®
- description
- Treatment according to standard clinical practice.
- interventionNames
- Drug: degarelix
Primary outcomes (1)
- measure
- Incidence of adverse events
- timeFrame
- Up to 12 months
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients who are eligible for the treatment of Firmagon® (degarelix) for injection according to the approved product label, and Firmagon® (degarelix) treatment decided before study enrolment. Moreover, patient should have not previously received Firmagon® (degarelix) for injection before the study commencement date at each site. - Indication: treatment of advanced, hormone-dependent prostate cancer. Exclusion Criteria: * Patients with previous or concurrent known hypersensitivity to any component of the drug.
References
Publications (0)
Data not yet available
No reference posted for this study.